Kelda M. Gardner

419 total citations
20 papers, 168 citations indexed

About

Kelda M. Gardner is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Kelda M. Gardner has authored 20 papers receiving a total of 168 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 8 papers in Oncology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Kelda M. Gardner's work include Acute Myeloid Leukemia Research (17 papers), Neutropenia and Cancer Infections (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Kelda M. Gardner is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Neutropenia and Cancer Infections (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Kelda M. Gardner collaborates with scholars based in United States and South Africa. Kelda M. Gardner's co-authors include Elihu H. Estey, Roland B. Walter, Pamela S. Becker, Paul C. Hendrie, Megan Othus, Kathleen Shannon Dorcy, Mary‐Elizabeth M. Percival, Bart L. Scott, Anna B. Halpern and Jennifer Vaughn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Kelda M. Gardner

19 papers receiving 166 citations

Peers

Countries citing papers authored by Kelda M. Gardner

Since Specialization

Citations

This map shows the geographic impact of Kelda M. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelda M. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelda M. Gardner more than expected).

Fields of papers citing papers by Kelda M. Gardner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelda M. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelda M. Gardner. The network helps show where Kelda M. Gardner may publish in the future.

Co-authorship network of co-authors of Kelda M. Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Kelda M. Gardner. A scholar is included among the top collaborators of Kelda M. Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelda M. Gardner. Kelda M. Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL) 2022 ·Blood ·Piyanuch Kongtim, Mary‐Elizabeth M. Percival, Timothy J. Martins, Guangrong Qin, (unknown), Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker	2
2	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility 2020 ·Haematologica ·Mary‐Elizabeth M. Percival, Megan Othus, (unknown), Kelda M. Gardner, (unknown), Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey	5
3	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia 2020 ·Blood ·(unknown), Anna B. Halpern, Megan Othus, Emily M. Huebner, (unknown), Kelda M. Gardner, Elihu H. Estey, Roland B. Walter, Colin D. Godwin	0
4	Relation between measurable residual disease and morphologic relapse in AML. 2020 ·Journal of Clinical Oncology ·(unknown), Megan Othus, Kelda M. Gardner, (unknown), Anna B. Halpern, Pamela S. Becker, Roland B. Walter, Elihu H. Estey, Mary‐Elizabeth M. Percival	1
5	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome 2020 ·Blood Advances ·(unknown), Kelda M. Gardner, Kathleen Shannon Dorcy, (unknown), Heather Smith, (unknown), (unknown), (unknown), Sunny J. Jones, (unknown), Bart L. Scott, Paul C. Hendrie, Mary‐Elizabeth M. Percival, Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey, Pamela S. Becker	19
6	Need for routine examination of left ventricular ejection fraction in patients with AML 2019 ·Leukemia ·(unknown), Kelda M. Gardner, (unknown), Anna B. Halpern, Emily M. Huebner, Mary‐Elizabeth M. Percival, (unknown), Mohamed L. Sorror, Pamela S. Becker, Roland B. Walter, Elihu H. Estey	2
7	Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms 2019 ·Blood ·Mary‐Elizabeth M. Percival, Megan Othus, (unknown), Kelda M. Gardner, (unknown), Anna B. Halpern, Paul C. Hendrie, Pamela S. Becker, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey	2
8	Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)? 2019 ·Journal of Clinical Oncology ·(unknown), Megan Othus, (unknown), Kelda M. Gardner, Mary‐Elizabeth M. Percival, Paul C. Hendrie, Elihu H. Estey	2
9	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML) 2019 ·Blood ·Jacob Appelbaum, (unknown), Kelda M. Gardner, (unknown), Paul C. Hendrie, Colin D. Godwin, Mary‐Elizabeth M. Percival, Anna B. Halpern, Bart L. Scott, Vivian G. Oehler, Roland B. Walter, Pamela S. Becker, Michael C. Jensen, Elihu H. Estey	3
10	Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm 2019 ·Blood ·Colin D. Godwin, Megan Othus, Mary‐Elizabeth M. Percival, Bart L. Scott, Pamela S. Becker, Kelda M. Gardner, Sioḃán Keel, Tejaswini Dhawale, Vivian G. Oehler, Janis L. Abkowitz, Anna B. Halpern, Paul C. Hendrie, (unknown), (unknown), Elihu H. Estey, Roland B. Walter	1
11	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow 2019 ·Blood ·Colin D. Godwin, Yi Zhou, Megan Othus, (unknown), Kelda M. Gardner, Brent L. Wood, Roland B. Walter, Elihu H. Estey	1
12	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms 2019 ·Blood ·Anna B. Halpern, Megan Othus, Kelda M. Gardner, (unknown), Mary‐Elizabeth M. Percival, Emily M. Huebner, Bart L. Scott, Pamela S. Becker, Paul C. Hendrie, Vivian G. Oehler, Elihu H. Estey, Roland B. Walter	3
13	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms 2018 ·Leukemia ·Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker, Mary‐Elizabeth M. Percival, Paul C. Hendrie, Kelda M. Gardner, (unknown), Sarah Buckley, (unknown), (unknown), Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey, Roland B. Walter	34
14	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML 2018 ·Blood ·Sylvia Chien, Jin Dai, John L. Magnani, (unknown), William E. Fogler, Helen Thackray, Kelda M. Gardner, Elihu H. Estey, Pamela S. Becker	5
15	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome 2015 ·JAMA Oncology ·Jennifer Vaughn, Megan Othus, (unknown), Kelda M. Gardner, (unknown), Paul C. Hendrie, Pamela S. Becker, Paul S. Pottinger, Elihu H. Estey, Roland B. Walter	36
16	G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm 2014 ·American Journal of Hematology ·Pamela S. Becker, Bruno C. Medeiros, Anthony S. Stein, Megan Othus, Frederick R. Appelbaum, Stephen J. Forman, Bart L. Scott, Paul C. Hendrie, Kelda M. Gardner, John M. Pagel, Roland B. Walter, (unknown), Brent L. Wood, Janis L. Abkowitz, Elihu H. Estey	10
17	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML) 2013 ·Leukemia Research Reports ·Victor A. Chow, Kathleen Shannon Dorcy, (unknown), Kelda M. Gardner, Pamela S. Becker, John M. Pagel, Paul C. Hendrie, Janis L. Abkowitz, Frederick R. Appelbaum, Elihu H. Estey	3
18	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. 2013 ·PubMed ·Roland B. Walter, (unknown), Kelda M. Gardner, Kathleen Shannon Dorcy, (unknown), Elihu H. Estey	36
19	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study 2013 ·Blood ·Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, (unknown), (unknown), Bart L. Scott, Paul C. Hendrie, Elihu H. Estey	2
20	Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study 2010 ·Blood ·Roland B. Walter, Stephanie J. Lee, Kelda M. Gardner, Andrei R. Shustov, Frederick R. Appelbaum, Elihu H. Estey	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact